Design Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DSGN Nasdaq 2836 www.designtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Design Therapeutics, Inc.

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - Apr 21st, 2025 8:01 pm
April 2025's Promising Penny Stocks - Apr 18th, 2025 12:05 pm
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - Apr 17th, 2025 12:00 pm
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors - Apr 17th, 2025 11:00 am
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why - Mar 12th, 2025 4:00 pm
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results - Mar 10th, 2025 11:07 am
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference - Mar 3rd, 2025 1:00 pm
US Penny Stocks To Watch In February 2025 - Feb 20th, 2025 12:10 am
3 Promising US Penny Stocks With Market Caps Under $900M - Jan 22nd, 2025 12:07 am
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - Nov 13th, 2024 1:00 pm
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - Nov 7th, 2024 9:01 pm
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Nov 6th, 2024 12:27 pm
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock - Sep 26th, 2024 11:55 am
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - Sep 10th, 2024 12:00 pm
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet - Aug 21st, 2024 1:55 pm
With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors - Aug 16th, 2024 10:07 am
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio - Aug 5th, 2024 12:00 pm
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains - May 23rd, 2024 12:50 am
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review - May 10th, 2024 7:36 pm
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones - May 8th, 2024 8:05 pm